1. Home
  2. FKWL vs GLTO Comparison

FKWL vs GLTO Comparison

Compare FKWL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Wireless Corp.

FKWL

Franklin Wireless Corp.

HOLD

Current Price

$4.09

Market Cap

53.5M

Sector

Utilities

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$25.33

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FKWL
GLTO
Founded
1981
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.5M
54.5M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
FKWL
GLTO
Price
$4.09
$25.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$41.00
AVG Volume (30 Days)
8.0K
31.5K
Earning Date
02-13-2026
03-18-2026
Dividend Yield
0.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$45,508,949.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.05
N/A
52 Week Low
$3.67
$2.01
52 Week High
$7.45
$38.33

Technical Indicators

Market Signals
Indicator
FKWL
GLTO
Relative Strength Index (RSI) 41.76 49.95
Support Level $4.05 $21.82
Resistance Level $4.19 $26.10
Average True Range (ATR) 0.05 2.47
MACD 0.00 -0.22
Stochastic Oscillator 28.57 30.29

Price Performance

Historical Comparison
FKWL
GLTO

About FKWL Franklin Wireless Corp.

Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: